Cassava Sciences reported 0 in Sales Revenues for its fiscal quarter ending in December of 2024.


Sales Change Date
Abbott USD 11.42B 1.06B Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
Biogen USD 2.6B 170M Jun/2025
Cassava Sciences 0 0 Dec/2024
Eisai JPY 202.65B 14.41B Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Geron USD 49M 9.4M Jun/2025
J&J USD 23.74B 1.85B Jun/2025
Merck USD 15.81B 280M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024